长期应用质子泵抑制剂的不良反应
作者：马一菡;罗斌阳;王一平;杨锦林;
Author：
收稿日期： 年卷（期）页码：2017,32(03):-321-325
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：质子泵抑制剂;长期使用;不良反应;低镁血症;骨质疏松;维生素B12缺乏;贫血;感染
Key words：
基金项目：四川省科技厅项目(编号:2015SZ0123)
中文摘要
质子泵抑制剂(PPIs)即H~+-K~+-ATP酶抑制剂,直接作用于位于胃黏膜细胞腔侧的质子泵,抑制H~+的分泌,可最直接和最有效地抑制胃酸的产生。但随着PPIs的广泛应用,越来越多的证据提示:长疗程(>1年)、长期超剂量(>1.75倍标准剂量)使用PPIs可能会导致多种严重不良反应,如引起低镁血症、骨质疏松、Vit B_(12)缺乏、贫血、肺部及肠道感染、增加息肉形成风险等。因此,必须关注长期应用PPIs可能对人体产生的影响,严格掌握用药指征及剂量疗程。文中综述了长期应用PPIs的不良反应。
参考文献
[1]Epstein M,Mc Grath S,Law F.Proton-pump inhibitors and hypomagnesemic hypoparathyroidism[J].N Engl J Med,2006,355(17):1834-1836.
[2]Cheungpasitporn W,Thongprayoon C,Kittanamongkolchai W,et al.Proton pump inhibitors linked to hypomagnesemia:A systematic review and meta-analysis of observational studies[J].Ren Fail,2015,37(7):1237-1241.
[3]Janett S,Camozzi P,Peeters GG,et al.Hypomagnesemia induced by long-term treatment with proton-pump inhibitors[J].Gastroenterol Res Practm,2015:951768.
[4]Park CH,Kim EH,Roh YH,et al.The association between the use of proton pump inhibitors and the risk of hypomagnesemia:A systematic review and meta-analysis[J].PLo S One,2014,9(11):e0112558.
[5]Hashimoto R,Matsuda T,Chonan A.Iron-deficiency anemia caused by a proton pump inhibitor[J].Internal Med,2014,53(20):2297-2299.
[6]Sarzynski E,Puttarajappa C,Xie Y,et al.Association between proton pump inhibitor use and anemia:A retrospective cohort study[J].Digest Dis Sci,2011,56(8):2349-2353.
[7]Yu EW,Bauer SR,Bain PA,et al,.Proton pump inhibitors and risk of fractures:A meta-analysis of 11 international studies[J].Am J Med,2011,124(6):519-526.
[8]Pouwels S,Lalmohamed A,Souverein P,et al.Use of proton pump inhibitors and risk of hip/femur fracture:A population-based case-control study[J].Osteoporos Int,2011,22(3):903-910.
[9]Zhou B,Huang Y,Li H,et al.Proton-pump inhibitors and risk of fractures:An update meta-analysis[J].Osteoporos Int,2016,27(1):339-347.
[10]Jung SB,Nagaraja V,Kapur A,et al.Association between vitamin B12 deficiency and long-term use of acid-lowering agents:A systematic review and meta-analysis[J].Intern Med J,2015,45(4):409-416.
[11]Hirschowitz BI,Worthington J,Mohnen J.Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors[J].Aliment Pharmacol Ther,2008,27(11):1110-1121.
[12]Den Elzen WPJ,Groeneveld Y,De Ruijter W,et al.Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals[J].Aliment Pharmacol Ther,2008,27(6):491-497.
[13]Henry EB,Carswell A,Wirz A,et al.Proton pump inhibitors reduce the bioavailability of dietary vitamin C[J].Aliment Pharmacol Ther,2005,22(6):539-545.
[14]Heidelbaugh JJ.Proton pump inhibitors and risk of vitamin and mineral deficiency:Evidence and clinical implications[J].Ther Adv Drug Saf,2013,4(3):125-133.
[15]Biswal S.Proton pump inhibitors and risk for Clostridium difficile associated diarrhea[J].Biomed J,2014,37(4):178-183.
[16]Fujimori S.What are the effects of proton pump inhibitors on the small intestine?[J].World J Gastroenterol,2015,21(22):6817-6819.
[17]Lombardo L,Foti M,Ruggia O,et al.Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy[J].Clin Gastroenterol Hepatol,2010,8(6):504-508.
[18]Kim JW,Lee KL,Jeong JB,et al.Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea[J].World J Gastroenterol,2010,16(28):3573-3577.
[19]Hong KS,Kang SJ,Choi JK,et al.Gastrointestinal tuberculosis is not associated with proton pump inhibitors:a retrospective cohort study[J].World J Gastroenterol,2013,19(2):258-264.
[20]Herzig SJ,Howell MD,Ngo LH,et al.Acid-suppressive medication use and the risk for hospital-acquired pneumonia[J].JAMA,2009,301(20):2120-2128.
[21]Gulmez SE,Holm A,Frederiksen H,et al.Use of proton pump inhibitors and the risk of community-acquired pneumonia:A population-based case-control study[J].Arch Intern Med,2007,167(9):950-955.
[22]Fohl AL,Regal RE.Proton pump inhibitor-associated pneumonia:Not a breath of fresh air after all?[J].World J Gastrointest Pharmacol Ther,2011,2(3):17-26.
[23]Juurlink DN,Gomes T,Ko DT,et al.A population-based study of the drug interaction between proton pump inhibitors and clopidogrel[J].CMAJ,2009,180(7):713-718.
[24]Juurlink DN,Gomes T,Mamdani MM,et al.The safety of proton pump inhibitors and clopidogrel in patients after stroke[J].Stroke,2011,42(1):128-132.
[25]Schmidt M,Johansen MB,Robertson DJ,et al.Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation[J].Aliment Pharmacol Ther,2012,35(1):165-174.
[26]Fontes-Carvalho R,Albuquerque A,Araujo C,et al.Omeprazole,but not pantoprazole,reduces the antiplatelet effect of clopidogrel:A randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction[J].Eur J Gastroenterol Hepatol,2011,23(5):396-404.
[27]Parri MS,Gianetti J,Dushpanova A,et al.Pantoprazole significantly interferes with antiplatelet effect of clopidogrel:Results of a pilot randomized trial[J].Int J Cardiol,2013,167(5):2177-2181.
[28]Kwok CS,Jeevanantham V,Dawn B,et al.No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel:Meta-analysis[J].Int J Cardiol,2013,167(3):965-974.
[29]Siller-Matula JM,Spiel AO,Lang IM,et al.Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel[J].Am Heart J,2009,157(1):148.e1-5.
[30]Jneid H,Anderson JL,Wright RS,et al.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction(updating the 2007 guideline and replacing the 2011 focused update):A report of the American college of cardiology foundation/American heart association task force on practice guidelines[J].Circulation,2012,126(7):875-910.
[31]Huang CZ,Lai RX,Mai L,et al.Relative risk factors associated with the development of fundic gland polyps[J].Eur J Gastroenterol Hepatol,2014,26(11):1217-1221.
[32]Freeman HJ.Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis[J].World J Gastroenterol,2008,14(9):1318-1320.
[33]Hagiwara T,Mukaisho K,Nakayama T,et al.Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori[J].Gut,2011,60(5):624-630.
[34]Graham DY,Genta RM.Long-term proton pump inhibitor use and gastrointestinal cancer[J].Curr Gastroenterol Rep,2008,10(6):543-547.
[35]Kallen BA.Use of omeprazole during pregnancy-no hazard demonstrated in 955 infants exposed during pregnancy[J].Eur J Obstet Gynecol Reprod Biol,2001,96(1):63-68.
[36]Diav-Citrin O,Arnon J,Shechtman S,et al.The safety of proton pump inhibitors in pregnancy:A multicentre prospective controlled study[J].Aliment Pharmacol Ther,2005,21(3):269-275.
[37]Pasternak B,Hviid A.Use of proton-pump inhibitors in early pregnancy and the risk of birth defects[J].N Engl J Med,2010,363(22):2114-2123.
[38]Gouraud A,Vochelle V,Descotes J,et al.Proton pump inhibitor-induced neutropenia:Possible cross-reactivity between omeprazole and pantoprazole[J].Clin Drug Investig,2010,30(8):559-563.
[39]Nozaki M,Suzuki T,Hirano M.Rhabdomyolysis associated with omeprazole[J].J Gastroenterol,2004,39(1):86.
[40]Bebarta VS,King JA,Mc Donough M.Proton pump inhibitorinduced rhabdomyolysis and hyponatremic delirium[J].Am J Emerg Med,2008,26(4):519.e1-2.
[41]Lindquist M,Pettersson M,Edwards IR,et al.Omeprazole and visual disorders:Seeing alternatives[J].Pharmacoepidemiol Drug Saf,1996,5(1):27-32.
[42]Sch9nh9fer PS,Werner B,Tr9ger U.Ocular damage associated with proton pump inhibitors[J].BMJ,1997,314(7097):1805.
[43]Abdul Razzak E,Tomas M,Tornero P,et al.Nine cases of allergy to omeprazole[J].J Investig Allergol Clin Immunol,2012,22(3):228-230.
【关闭】
